---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-093244"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-08-25T11:30:33+00:00"
generated_at: "2026-08-25T11:35:18.489573+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Incannex doses first patient in DReAMzz Phase 2 study of IHL-42X for sleep apnea

## Summary
- First patient dosed in DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea (OSA).
- All 14 U.S. clinical trial sites have IRB approval; drug product manufactured and patient screening underway.
- Builds on Phase 2 RePOSA results: statistically significant AHI reductions vs placebo, individual reductions up to 83%.
- FDA granted Fast Track designation to IHL-42X program, supporting expedited development and review.
- Study aims to optimize dose selection and inform design of planned Phase 3 development program.

## SEC filing metadata
- accession: 0001213900-26-093244
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-08-25T11:30:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/0001213900-26-093244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea0303140-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-093244
- JSON: https://secwatch.observer/filing/0001213900-26-093244.json
- Plain text: https://secwatch.observer/filing/0001213900-26-093244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.